From the Center for Translational Medicine and Department of Pathology, Anatomy, and Cell Biology, Thomas Jefferson University, Philadelphia, PA; and Department of Cardiology, Changhai Hospital, Second Military Medical University, Shanghai, China.
Circ Res. 2013 Oct 25;113(10):1117-27. doi: 10.1161/CIRCRESAHA.113.301306. Epub 2013 Sep 6.
Abnormal phenotypic switch of vascular smooth muscle cell (VSMC) is a hallmark of vascular disorders such as atherosclerosis and restenosis after angioplasty. MicroRNAs (miRNAs) have emerged as important regulators for VSMC function, and we recently identified miR-663 as critical for controlling human aortic smooth muscle cell proliferation.
To investigate whether miR-663 plays a role in human VSMC phenotypic switch and the development of neointima formation.
By using quantitative reverse-transcription polymerase chain reaction, we found that miR-663 was significantly downregulated in human aortic VSMCs on platelet-derived growth factor treatment, whereas expression was markedly increased during VSMC differentiation. Furthermore, we demonstrated that overexpression of miR-663 increased expression of VSMC differentiation marker genes, such as smooth muscle 22α, smooth muscle α-actin, calponin, and smooth muscle myosin heavy chain, and potently inhibited platelet-derived growth factor-induced VSMC proliferation and migration. We identified the transcription factor JunB and myosin light chain 9 as downstream targets of miR-663 in human VSMCs, because overexpression of miR-663 markedly inhibited expression of JunB and its downstream molecules, such as myosin light chain 9 and matrix metalloproteinase 9. Finally, we showed that adeno-miR-663 markedly suppressed the neointimal lesion formation by ≈50% in mice after vascular injury induced by carotid artery ligation, specifically via decreased JunB expression.
These results indicate that miR-663 is a novel modulator of human VSMC phenotypic switch by targeting JunB/myosin light chain 9 expression. These findings suggest that targeting miR-663 or its specific downstream targets in human VSMCs may represent an attractive approach for the treatment of proliferative vascular diseases.
血管平滑肌细胞(VSMC)表型转换异常是血管疾病的标志,如动脉粥样硬化和血管成形术后再狭窄。微小 RNA(miRNA)已成为 VSMC 功能的重要调节因子,我们最近发现 miR-663 对控制人主动脉平滑肌细胞增殖至关重要。
研究 miR-663 是否在人 VSMC 表型转换和新生内膜形成中发挥作用。
通过定量逆转录聚合酶链反应,我们发现 miR-663 在血小板衍生生长因子处理的人主动脉 VSMC 中显著下调,而在 VSMC 分化过程中表达明显增加。此外,我们证明 miR-663 的过表达增加了 VSMC 分化标志物基因的表达,如平滑肌 22α、平滑肌α-肌动蛋白、钙调蛋白和平滑肌肌球蛋白重链,并有力地抑制了血小板衍生生长因子诱导的 VSMC 增殖和迁移。我们鉴定了转录因子 JunB 和肌球蛋白轻链 9 是 miR-663 在人 VSMCs 中的下游靶标,因为 miR-663 的过表达显著抑制了 JunB 及其下游分子如肌球蛋白轻链 9 和基质金属蛋白酶 9 的表达。最后,我们表明,腺病毒-miR-663 通过降低 JunB 表达,在血管损伤诱导的颈动脉结扎后,小鼠的新生内膜病变形成减少约 50%。
这些结果表明,miR-663 通过靶向 JunB/肌球蛋白轻链 9 表达,是一种新型的人 VSMC 表型转换调节剂。这些发现表明,针对人 VSMCs 中的 miR-663 或其特定下游靶点可能代表治疗增殖性血管疾病的一种有吸引力的方法。